Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase

Kidney International

Volumn 57, Issue 2, 2000, Pages 446-454

  Abe, Akira ^a,b,c   Arend, Lois J ^a,b,c   Lee, Lihsueh ^a,b,c   Lingwood, Clifford ^a,b,c   Brady, Roscoe O ^a,b,c   Shayman, James A ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Fabry cell lines; Globotriaosylceramide; Verotoxin; X linked disorder; galactosidase A

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GLYCOSPHINGOLIPID; MIGLUSTAT;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FABRY DISEASE; HUMAN; HUMAN CELL; LYMPHOBLAST; LYMPHOCYTE; PRIORITY JOURNAL;

EID: 0033930125     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00864.x     Document Type: Article

References (19)

1. 1. BRADY RO, GAL AE, BRADLEY RM, MARTENSSON E, WARSHAW AL, LASTER L: Enzymatic defect in Fabry's disease: Ceramide trihexosidase deficiency. N Engl J Med 276:1163-1167, 1967
2. 2. DESNICK RJ, IOANNOU YA, ENG CM, SCRIVER CR (EDS): α-Galactosidase A Deficiency: Fabry Disease in the Metabolic and Molecular Bases of Inherited Disease, edited by DESNICK RJ, IOANNOU YA, ENG CM, SERWAR CR, New York, McGraw-Hill, 1995, pp 2741-2784
3. 3. NYHOLM PG, MAGNUSSON G, ZHENG Z, NOREL R, BINGINGTON-BOYD B, LINGWOOD CA: Two distinct binding sites for globotriaosyl ceramide on verotoxins: Identification by molecular modeling and confirmation using deoxy analogues and a new glycolipid receptor for all verotoxins. Chem Biol 3:263-275, 1996
4. 4. SHAYMAN JA, ABE A: Glucosylceramide synthase: Assay and properties. Methods Enzymol 311:42-49, 1999
5. 5. SHAYMAN JA, LEE L, ABE A, SHU L: Inhibitors of glucosylceramide synthase. Methods Enzymol 311:373-387, 1999
6. 6. ABE A, RADIN NS, SHAYMAN JA, WOTRING LL, ZIPKIN RE, SIVAKUMAR R, RUGGIERI JM, CARSON KG, GANEM B: Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res 36:611-621, 1995
7. 7. LEE L, ABE A, SHAYMAN JA: Improved inhibitors of glucosylceramide synthase. J Biol Chem 274:14662-14669, 1999
8. 8. MEDIN JA, TUDOR M, SIMOVITCH R, QUIRK JM, JACOBSON S, MURRAY GJ, BRADY RO: Correction in trans for Fabry disease: Expression, secretion, and uptake of α-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci USA 93:7917-7922, 1996
9. 9. SCHAPIRO FB, LINGWOOD C, FURUYA W, GRINSTEIN S: pH-independent retrograde targeting of glycolipids to the Golgi complex. Am J Physiol 274:C319-C332, 1998
10. 10. AMES BN: Assay of inorganic phosphate, total phosphate, and phosphatases. Methods Enzymol 8:115-118, 1966
11. 11. ROHRER J, SCHWEITZER A, JOHNSON KF, KORNFELD S: A determinant in the cytoplasmic tail of the cation-dependent mannose 6-phosphate receptor prevents trafficking to lysosomes. J Cell Biol 130:1297-1306, 1995
12. 12. PLATT FM, NEISES GR, REINKENSMEIER G, TOWNSEND MJ, PERRY VH, PROIA RL, WINCHESTER B, DWEK RA, BUTTERS TD: Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276:428-431, 1997
13. 13. JEYAKUMAR M, BUTTERS TD, CORTINA-BORJA M, HUNNAM V, PROIA RL, PERRY VH, DWEK RA, PLATT FM: Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 96:6388-6393, 1999
14. 14. DESNICK RJ, DEAN KJ, GRABOWSKI G, BISHOP DF, SWEELEY CC: Enzyme therapy in Fabry disease: Differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes. Proc Natl Acad Sci USA 76:5326-5330, 1996
15. 15. PLATT FM, NEISES GR, DWEK RA, BUTTERS TD: N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 269:8362-8365, 1994
16. 16. LIU Y, WADA R, KAWAI H, SANGO K, DENG C, TAI T, MCDONALD MP, ARAUJO K, CRAWLEY JN, BIERFREUND U, SANDHOFF K, SUZUKI K, PROIA RL: A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J Clin Invest 103:497-505, 1999
17. 17. RANI CS, ABE, A, CHANG Y, SALTIEL AR, RADIN NS, SHAYMAN JA: Cell cycle arrest induced by an inhibitor of glucosylceramide synthase: Correlation with cyclin-dependent kinases. J Biol Chem 270:2859-2867, 1995
18. 18. ABE A, SHAYMAN JA, RADIN NS: A novel enzyme that catalyzes the esterification of N-acetylsphingosine. J Biol Chem 271:14383-14389, 1996
19. 19. ABE A, SHAYMAN JA: Purification and characterization of I-O-acylceramide synthase, a novel phospholipase A2. J Biol Chem 11-8467-8474, 1998